Ketamine is a long-used anesthetic that, at lower doses given in clinical settings, can lift severe depression within hours in people who have not responded to standard antidepressants, which usually take weeks to work. It appears to act mainly by blocking NMDA glutamate receptors, which triggers a burst of glutamate signaling and rapid growth of new synaptic connections in the brain.
The effects are often short-lived, so repeated dosing is typically needed, and it can cause dissociation, raised blood pressure, and abuse concerns. The FDA approved esketamine, a related form given as a nasal spray under medical supervision, for treatment-resistant depression in 2019.